Retatrutide Research: What Changed and What Is Still Unknown
Phase 1b was an early small test. Early studies checked benefit and common harm, while Phase 3 is testing larger groups.
What retatrutide research can tell you about people
What have human studies found so far? Retatrutide isn't approved, but studies have tested hunger, blood sugar, and calorie use.
At the highest amount, average body weight fell about 24% over 48 weeks. People with type 2 diabetes also had lower sugar and less liver fat.
Phase 1b is an early test in a small group; the b marks a later part of the first stage. Phase 2 then looks for benefit and common harm.
A second study focused on liver fat. Phase 3 now uses much larger groups before an approval decision.
Those Phase 2 findings don't settle long-term safety. Retatrutide research remains unfinished, so you still need to treat the drug as unproved for your care.
What keeps the drug working in your body for days
Scientists started with a meal hormone that helps call for insulin after food. They added a fat-like tail that hooks onto albumin, a blood protein, helping the drug last about 6 days [4].
In 2024, researchers studied frozen samples to see where retatrutide touched three hormone-reading proteins on cells [3]. The pictures came from lab samples, not from inside a person.
- The meal-hormone protein reacted most strongly. This may affect your body fat and add weight loss beyond drugs that copy only GLP-1, the hunger hormone [3].
- The glucagon protein reacted least strongly. Glucagon may raise calorie use and draw fat from the liver without raising sugar too far [3].
- The GLP-1 hunger-hormone protein fell between the other two. This part mainly curbs hunger and helps your body put out insulin [3].
In lab-grown cells, each protein reacted when retatrutide touched it [3]. The dish test measured that reaction, not weight loss or safety in a person.
A 2025 review linked glucagon with added calorie burn beyond drugs that copy GIP and GLP-1 [11]. That supports more testing, but it doesn't prove a better result for you.
What Phase 1b found in the first people studied
In 2022, Phase 1b enrolled 72 adults with type 2 diabetes. This early test used the later part of the first study stage.
Their three-month sugar-test results ran from 7.0–10.5%, showing that sugar had stayed high. They received weekly shots for 12 weeks [4].
The amounts were 0.5, 1.5, or 3 mg. Another group moved through 3/6/9/12 mg under the study team's care.
The drug stayed in the body for about 6 days, supporting one shot each week [4]. The top-amount group lost −8.96 kg beyond the loss seen with placebo [4].
When you see placebo here, it means the comparison shot without retatrutide. The team was 90% sure the true extra loss fell between −11.16 and −6.75 kg.
At 3 mg, average daily blood sugar fell [4]. Side effects arose in 63%, mostly as stomach or bowel trouble [4].
Phase 1b showed the drug's time in the bloodstream. It also gave Phase 2 its study amounts, up to 12 mg; those figures can't choose your amount.
What Phase 2 changed in your body weight: −24.2% at 48 weeks
In 2023, the Phase 2 obesity study enrolled 338 adults. Their BMI compared weight with height. It was 30 or more, or 27 or more with another health problem.
Each person received a weekly shot of 1, 4, 8, or 12 mg, or placebo, for 48 weeks [1]. A placebo is the comparison shot without retatrutide.
| Dose | Mean body-weight change at 48 weeks |
|---|---|
| Placebo | −2.1% |
| 1 mg | −8.7% |
| 4 mg | −17.3% |
| 8 mg | −22.8% |
| 12 mg | −24.2% |
Blood pressure and blood fats improved. So did the three-month sugar test. A 2024 review discussed how those changes may relate to heart risk, but it did not show fewer heart attacks [8].
At higher amounts, most people had some stomach or bowel trouble. Nausea caused an 18% stop rate at 12 mg [1].
Heart rate rose further when researchers used larger amounts. The top rise came near week 24 [1], which is one risk you would need explained.
What Phase 2 changed for people with type 2 diabetes
In 2023, this study enrolled 281 adults with type 2 diabetes. They received weekly shots from 0.5–12 mg, raised in steps, over 36 weeks [2].
Doctors use one blood test to show the average from the prior three months. At 24 weeks, it fell −2.02% with 12 mg and −0.01% with placebo [2].
Lower is better, and placebo means the comparison shot without retatrutide. The report shows the change but leaves out a normal ending number for you.
Body weight fell −16.94%, compared with −3.00% at 36 weeks [2]. Researchers recorded neither a death nor a severe sugar drop [2].
Trouble in the stomach or bowel was mild or moderate and affected 35% [2]. People who came in on insulin had to use less while the study team watched their health [2].
The blood-test change and more than 16% weight loss support more diabetes study. Whether your doctor can use retatrutide depends on Phase 3 results [12], not hope.
What happened to liver fat: −82.4% at 24 weeks
In 2024, a smaller Phase 2a study enrolled 98 adults who were overweight or had obesity. This means an early part of the second study stage.
Their scans showed at least 10% liver fat, but they did not have type 2 diabetes [5]. Doctors call this fatty liver disease. The scan checked the change at 24 weeks.
| Dose | Liver-fat change from the start |
|---|---|
| Placebo | +0.3% |
| 1 mg | −42.9% |
| 4 mg | −57.0% |
| 8 mg | −81.4% |
| 12 mg | −82.4% |
At 12 mg, 86% had liver fat under the normal 5% mark by 24 weeks [5]. The change lasted through 48 weeks and measured −86.0% at 12 mg [5].
The drop supported more liver work in TRIUMPH Phase 3. It doesn't yet prove that your liver would avoid lasting harm.
How does retatrutide work in your body
Retatrutide copies parts of three hormones. One is GLP-1, the hunger hormone, which may curb your hunger. As sugar rises, it can also help insulin enter your blood.
After food, the second hormone helps insulin work and may change fat storage. Glucagon can raise calorie use and help draw fat from the liver.
Approved obesity drugs don't copy this same set. In 2024, frozen lab samples showed retatrutide joined to the protein that reads each hormone [3].
That fit offers one reason for the drug's effects. Years of testing are still needed before you know its long-term safety.
What FDA approval still requires for retatrutide
Retatrutide wasn't FDA-approved in mid-2026. Phase 3 teams were still testing it in people.
Eli Lilly had not yet sent an approval request to the FDA. The FDA hadn't given retatrutide an approved use.
In 2025, a review found retatrutide in active Phase 3 work with 13 other obesity drugs [7]. None had yet reported the main results needed for approval.
Even if the TRIUMPH Phase 3 studies succeed, an FDA review would still follow. Your wait could last years after Phase 3 ends, so you can't count on a date.
What retatrutide availability means right now
Can your doctor prescribe retatrutide now? No; in mid-2026, it was available only inside a human study.
No agency had approved its form, its use, or its sale. Products marked for research aren't checked for the right drug, clean contents, or safe shots.
The FDA has acted against sellers under federal drug law [1]. ClinicalTrials.gov is the place for you to read listed study and enrollment details.
When will retatrutide be available if the studies go well
By mid-2026, Eli Lilly had given no date for an FDA filing. The Phase 3 TRIUMPH work remained unfinished.
Similar obesity drugs have taken 3–5 years from the start of Phase 3 to approval, when they passed. That history can't predict an approval request for retatrutide.
The 2025 review placed the drug among the furthest along in this Phase 3 group [7]. The timing still rests on study results, the safety review, and the FDA's decision.
There is no approved date when you can expect it. Giving you a firm date today would only be guesswork.